-- 周三盘后交易中,受国内供应增加影响,美国天然气期货价格下跌。与此同时,有报道称伊朗正在重新评估一项由美国支持的和平方案,该方案有望缓解霍尔木兹海峡的紧张局势,并恢复这一关键咽喉要道的航运,受此消息影响,更广泛的能源市场走低。 亨利枢纽天然气期货近月合约和连续基准价格均下跌2.37%,至每百万英热单位2.722美元。 据Barchart援引彭博新能源财经(BNEF)的数据称,受季节性维护影响,美国液化天然气(LNG)原料气输送量本周下降7.8%,至每日177亿立方英尺,为三个多月以来的最低水平。 LNG供应放缓导致更多天然气流入国内市场,加剧了人们对库存增加的担忧。截至4月24日,美国天然气库存水平已比五年平均水平高出7.7%。 美国能源信息署(EIA)将于周四发布最新的每周库存数据。 Gelber & Associates预测,截至5月1日当周,天然气注入量将达到800亿立方英尺(Bcf),低于去年同期的1040亿立方英尺,也低于五年平均水平770亿立方英尺。 该公司在周三的一份报告中表示:“如果实际数据接近我们的预期,市场可能会继续关注液化天然气原料气供应的复苏情况,以及5月下旬的电力消耗能否支撑更强劲的价格底部。” 报告还指出:“如果注入量大幅增加,将进一步强化春季维护和多变天气仍在抑制价格上涨的观点;而如果注入量较低,则有利于价格在下一轮热量调整前保持支撑。” 与此同时,彭博新能源财经(BNEF)的数据显示,周三美国本土48州干气日产量为1109亿立方英尺,同比增长5.5%;而Gelber & Associates的数据显示,加拿大净进口量仍然较低,为45亿立方英尺/日。 据Gelber & Associates称,美国本土48州天然气需求量为722亿立方英尺/日,较上年同期增长9.5%,其中住宅和商业需求量为172亿立方英尺/日,为天然气需求提供了最强劲的支撑,这得益于季末天气带来的天然气需求回升。 预计随着美国国家气象局周三对落基山脉大部分地区发布冬季风暴预警,天然气需求将进一步走强。这些地区在周二和周三遭遇了一场异常晚来的暴风雪。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.